Cabergoline
Cabergoline
Definition
A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.
Also known as 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, CABERGOLINE, Dostinex, FCE 21336 — per NCIT
Also identified as
- ATC G02CB03 per RXNORM
- ATC N04BC06 per RXNORM
- NCIT NCIT:C47428 per NCIT
- SCTID 109139002 per RXNORM
- SCTID 386979007 per RXNORM
- UNII LL60K9J05T per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Adenoma | may treat | MEDRT · Public domain (U.S. Government work) |
| Hyperprolactinemia | may treat | MEDRT · Public domain (U.S. Government work) |
| Parkinson's disease | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Central nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.